MRNA - Moderna, Inc.
| Previous close | 21.01 |
| Open | 21.50 |
| Bid | 20.62 x 4000 |
| Ask | 20.99 x 1200 |
| Day's range | 20.55 - 21.50 |
| 52-week range | 11.54 - 29.79 |
| Volume | 3,348,525 |
| Avg. volume | 1,753,814 |
| Market cap | 6.872B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.92 |
| Earnings date | 05 Nov 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.25 |
- Business Wire
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
Moderna builds on clinical validation of systemic delivery with two additional development candidates in new autoimmune therapeutic area.
- Business Wire
Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
Moderna announces additional positive Phase 1 data from its cytomegalovirus (CMV) vaccine (mRNA-1647) and first participant dosed in Phase 2 study
- Business Wire
Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference
Moderna to provide business and pipeline updates at the 2020 J.P. Morgan Healthcare Conference.
- Simply Wall St.
Did You Miss Moderna's (NASDAQ:MRNA) 20% Share Price Gain?
On average, over time, stock markets tend to rise higher. This makes investing attractive. But not every stock you buy...
- Zacks
5 Biotech Stocks Set for Continued Rally in 2020
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
- Business Wire
Moderna Announces Key 2020 Investor and Analyst Events
Moderna announced its key 2020 investor and analyst event schedule, including Manufacturing & Digital Day, Vaccines Day, Science Day and R&D Day.
- Business Wire
François Nader, M.D., Joins Moderna’s Board of Directors
François Nader, M.D., joins Moderna’s Board of Directors.
- Business Wire
Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York City on December 3rd at 9:00 a.m. ET. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
- Zacks
The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target
The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target
- Zacks
5 Top Stocks That Surged Amid Volatility in the Last 7 Days
Volatility has gripped Wall Street since the past week owing to several conflicting news about the signing of an interim trade deal between the United States and China.
- Zacks
Moderna, Inc. (MRNA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Moderna, Inc. (MRNA).
- Zacks
Top Ranked Momentum Stocks to Buy for November 8th
Top Ranked Momentum Stocks to Buy for November 8th
- Business Wire
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
Positive interim results announced from Phase 1 CMV vaccine study
- Business Wire
Moderna to Present at Credit Suisse 28th Annual Healthcare Conference
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Lorence Kim, M.D., Chief Financial Officer, will participate in the Credit Suisse 28th Annual Healthcare Conference in Scottsdale, Arizona on November 13th at 9:45 a.m. ET. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations.
- Business Wire
Moderna Named Top Employer by Science for Fifth Consecutive Year
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced it has been named one of the global biopharmaceutical industry’s top employers in Science and Science Careers’ 2019 Top Employers Survey for the fifth consecutive year. Moderna was ranked 11th on the list this year.
- Business Wire
Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia (PA). The Company announced the open IND for mRNA-3927 on September 30, 2019.
- Business Wire
Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2019 to report its third quarter 2019 financial results and provide a corporate update. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for 30 days following the call. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
- Business Wire
Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced data presentations regarding two of its wholly owned prophylactic mRNA vaccines at IDWeek in Washington, D.C. The presentations include interim Phase 1 data from its combination vaccine against the respiratory viruses human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3) (mRNA-1653) and preclinical data from its Zika vaccine (mRNA-1893).
- Business Wire
Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the U.S. Food and Drug Administration (FDA) has completed their review of the Investigational New Drug (IND) application for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia (PA) and allowed it to proceed to clinic. “We are excited to have a second open IND for a rare disease program and are preparing to move mRNA-3927 into a Phase 1/2 clinical trial in patients with propionic acidemia,” said Tal Zaks, M.D., Ph.D., chief medical officer at Moderna. “There are no approved therapies to treat the underlying cause of propionic acidemia, a rare metabolic disorder that can lead to a toxic buildup of acids in the body.
- Simply Wall St.
What Kind Of Investor Owns Most Of Moderna, Inc. (NASDAQ:MRNA)?
The big shareholder groups in Moderna, Inc. (NASDAQ:MRNA) have power over the company. Institutions will often hold...
